Article Details

Halozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week High Following Analyst Upgrade

Retrieved on: 2020-11-25 19:41:15

Tags for this article:

Click the tags to see associated articles and topics

Halozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week High Following Analyst Upgrade. View article details on hiswai:

Excerpt

<b>Schonfeld Strategic Advisors</b> LLC now owns 71,900 shares of the biopharmaceutical company's stock worth $1,890,000 after buying an additional ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo